Automate Your Wheel Strategy on CMPS
With Tiblio's Option Bot, you can configure your own wheel strategy including CMPS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CMPS
- Rev/Share 0.0
- Book/Share 2.1915
- PB 1.994
- Debt/Equity 0.0536
- CurrentRatio 10.1826
- ROIC -0.6337
- MktCap 405747185.0
- FreeCF/Share -1.615
- PFCF -2.8168
- PE -2.8285
- Debt/Assets 0.0328
- DivYield 0
- ROE -0.7163
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CMPS | Evercore ISI | Outperform | In-line | $11 | $6 | June 23, 2025 |
| Initiation | CMPS | Stifel | -- | Buy | -- | $11 | Feb. 27, 2025 |
News
COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Neutral
I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 data in 2H 2026 and ongoing PTSD and anorexia programs, but risks remain if future data underwhelms. The treatment resistant depression market in the 7 major markets is expected to reach $6.70 billion by 2035.
Read More
Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint
Published: June 23, 2025 by: Proactive Investors
Sentiment: Positive
Compass Pathways (NASDAQ:CMPS) has reported positive results from its Phase 3 trial of its synthetic formulation of psilocybin, COMP360, in patients with treatment-resistant depression (TRD), with the trial meeting its primary endpoint. A single 25 mg dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo, with a mean difference of 3.6 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6.
Read More
Compass Pathways' depression drug succeeds late-stage trial
Published: June 23, 2025 by: Reuters
Sentiment: Positive
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.
Read More
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint is the difference in change from baseline in the Montgomery.
Read More
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
Published: June 18, 2025 by: Proactive Investors
Sentiment: Positive
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Read More
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical Officer Steve Levin - Chief Patient Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Athena Chin - TD Cowen Sumant Kulkarni - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
Read More
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in.
Read More
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pat.
Read More
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Published: April 22, 2025 by: Business Wire
Sentiment: Neutral
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on t.
Read More
Compass Pathways: Betting On The Future Of Psilocybin Therapy
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
Compass Pathways is positioned to leverage regulatory tailwinds and compelling clinical data, despite broader skepticism and high cash burn in the psychedelic biotech sector. The company has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before needing additional capital. COMP360 shows promise in treating treatment-resistant depression and PTSD, with significant clinical trial results and potential long-term economic benefits.
Read More
COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
COMPASS Pathways plc (NASDAQ:CMPS ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Lori Englebert - Chief Commercial Officer Teri Loxam - Chief Financial Officer Michael Gold - Chief Research & Development Officer Guy Goodwin - Chief Medical Officer Steve Levine - Chief Patient Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Paul Matteis - Stifel Ritu Baral - TD Cowen Charles Duncan - Cantor Leonid Timashev - RBC Capital Markets Patrick Trucchio - H.C. Wainwright & Co. François …
Read More
About COMPASS Pathways plc (CMPS)
- IPO Date 2020-09-18
- Website https://compasspathways.com
- Industry Medical - Care Facilities
- CEO Kabir Kumar Nath
- Employees 166